KALSIOM SAS
The startup develops monoclonal antibodies that modulate calcium-signaling pathways in lymphocytes to address B-cell dysfunction in autoimmune disorders. This targeted approach aims to provide effective therapies for conditions with significant unmet medical needs.
- Biotechnology
Updated 6 months ago
Funding
Raised to date
$2.5MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops monoclonal antibodies that modulate calcium-signaling pathways in lymphocytes to address B-cell dysfunction in autoimmune disorders. This targeted approach aims to provide effective therapies for conditions with significant unmet medical needs.